Merck (MRK) succeeds in a Phase 2b/3 trial for diabetic macular edema as intravitreal injection remigromig shows ...

D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need  First patients have been enrolled in 4SIGHT global Phase 3 trial ...

D Molecular Therapeutics remains a Buy as 4D-150 enters phase 3 for wet AMD/DME, cutting injections up to 87%. Click for more ...

W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...

Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections. Diabetic macular edema affects about 5% to 7% of people ...

An experimental eye injection developed by Merck has met its main goal in a clinical trial involving patients with diabetic ...

Researchers have found in a recent study that intravitreal 0.5 mg conbercept improved visual and anatomical outcomes in ...

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs MISSISSAUGA, ON, Aug. 15, 2025 /CNW/ - Hoffmann-La ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...